The Majority of Expedited Investigational New Drug Safety Reports Are Uninformative

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Jonathan P JarowSean Khozin

Abstract

Sponsors of human drug and biologic products subject to an investigational new drug (IND) application are required to distribute expedited safety reports of serious and unexpected suspected adverse reactions to participating investigators and the FDA to assure the protection of human subjects participating in clinical trials. On September 29, 2010, the FDA issued a final rule amending its regulations governing expedited IND safety reporting requirements that revised the definitions used for reporting and clarified when to submit relevant and useful information to reduce the number of uninformative reports distributed by sponsors. From January 1, 2006, to December 31, 2014, the FDA's Office of Hematology and Oncology Products received an average of 17,686 expedited safety reports per year. An analysis of FDA submissions by commercial sponsors covering this time period suggested a slight increase in the number of expedited safety reports per IND per year after publication of the final rule. An audit of 160 randomly selected expedited safety reports submitted to the FDA's Office of Hematology and Oncology Products in 2015 revealed that only 22 (14%) were informative. The submission of uninformative expedited safety reports by comm...Continue Reading

References

Jun 10, 2011·The New England Journal of Medicine·Rachel Behrman ShermanRobert J Temple
Nov 10, 2015·Statistics in Biopharmaceutical Research·Janet WittesJudith Kramer
Mar 1, 2014·Therapeutic Innovation & Regulatory Science·Patrick ArchdeaconJudith M Kramer

❮ Previous
Next ❯

Citations

Jul 31, 2016·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Stephen A Goldman
Jul 13, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Saiama N WaqarGideon M Blumenthal
Mar 28, 2017·Clinical Trials : Journal of the Society for Clinical Trials·Elad Sharon
Mar 28, 2017·Clinical Trials : Journal of the Society for Clinical Trials·Raymond PerezAnnemarie Forrest
Mar 22, 2016·Nature Reviews. Clinical Oncology·Apostolia M Tsimberidou
Jun 1, 2017·American Society of Clinical Oncology Educational Book·Julie M VoseFrancis Giles
Dec 14, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laura A LevitJulie M Vose
Jan 1, 2017·Therapeutic Innovation & Regulatory Science·Jonathan Seltzer, Amit Bhattacharyya
Oct 5, 2019·BMJ : British Medical Journal·Leeza Osipenko
Mar 23, 2017·European Heart Journal·Martin J LandrayBarbara Casadei
Aug 7, 2018·Therapeutic Innovation & Regulatory Science·Jonathan P Jarow, Richard Moscicki
Apr 14, 2021·Cancer·Dan T VoglRobert H Vonderheide
Jul 17, 2021·Frontiers in Pharmacology·Xian SuHaixue Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.